Joe Pitts

I believe Congress and the Administration have a moral responsibility and duty to solve the problems before they fail the millions of people who depend on them.

I have to say I am disappointed. This budget does not balance. Ever.

This is in direct violation of federal law under the Weldon amendment and a direct assault on conscience rights.

The Chair thanks the gentlelady. That concludes the questions that we have here. We have follow-up questions. We will submit those to you in writing. We ask that you please respond promptly.

I was concerned that CMS finalized its Part B payment policy for biosimilars last year combining all biosimilars into one average sales price calculation and payment code.

I supported the creation of a pathway for biosimilars, and for empowering FDA with the authority and resources to ensure that biosimilars are safely available here in the U.S. for the patients that need them the most.

FDA approved the first biosimilar in March 2015 and is convening an advisory committee next week to consider a second application.

In 2009, this committee passed the Biologics Price Competition and Innovation Act (BPCIA) by a vote of 47 to 11.

Biologics are used to treat a number of serious diseases and conditions and have improved the lives of millions of Americans.

I urge my colleagues to support both of these amendments and the underlying resolution.

The chair thanks the gentleman.

I urge all Members to support this important bipartisan, bicameral legislation. Mr. Speaker, I yield back the balance of my time.

I am pleased to yield 1 minute to the gentleman from West Virginia (Mr. Jenkins), a leader on this issue.

I encourage my colleagues to support this commonsense, bipartisan bill. I yield back the balance of my time.

In my mind that would not include issuing guidances, fiats that are expected to be followed, but rather, you go through the normal administrative procedures.

I am eager to hear what Dr. Conway has to say on the matter.

In order to advance each of them, we must establish a regulatory environment that fosters the development of, and access to, innovative, accurate, and reliable diagnostic testing.

This bill would authorize the appropriations of $16 million for HHS to identify and publish quality measures for maternal and infant health.

Today's hearing will review the accuracy of eligibility and financing determinations made by the Center of Medicare and Medicaid Services, CMS.

As we have heard from our senior constituents, they rely on the Part D program and Congress has a responsibility to ensure that the MTM program is working as intended.

I also appreciate DEA's efforts to combat the recent influx of incredibly dangerous synthetic drugs hitting communities across the country.

There are many of our constituents and their families that still need help, and I applaud my colleagues for working on legislation with that goal in mind.

These startling statistics should concern all of us.

Prescription drug abuse does not discriminate: it is not limited by geography, income, or age.

Thank you very much for coming.